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Background:  Higher rates of adverse cardiac events have been observed in patients with small vessel disease. Thus, we compared an everolimus-
eluting stent (EES) to a paclitaxel-eluting stent (PES) for treatment of small (<2.5 mm) and larger vessels (≥2.5 mm) in a pooled analysis of the 
SPIRIT III and SPIRIT IV trials.
Methods:  In SPIRIT III (n=1001) and SPIRIT IV (n=3687), 4688 total patients were randomized 2:1, EES vs. PES, and data pooled for a patient 
level analysis. Inclusion and exclusion criteria were comparable with similar baseline characteristics and event definitions. EES vs. PES performance 
in small (n=1019) and larger vessels (n=2586) was evaluated at 1 year.
Results:  Mean reference vessel diameter (RVD) assessed by quantitative coronary angiography in patients with small and larger vessels was 2.25 
± 0.19 and 2.99 ± 0.35 mm respectively. Lesion length, RVD, and % diabetics were matched between stent types. Relative benefits of EES vs. PES 
were comparable in small and larger vessels (p interaction = ns). At 1 year, EES vs. PES small vessel patients showed a significant reduction in major 
adverse cardiac events (4.5% vs. 7.9%, p=0.04) and a significant reduction in target lesion failure (4.4% vs. 7.9%, p=0.03) favoring EES. Target 
lesion revascularization was also significantly reduced by 56% in small vessels, EES vs. PES (2.4% vs. 5.5%, p=0.02).
Conclusion:  In SPIRIT III and IV, absolute reduction in TLR and composite safety and efficacy measures were particularly marked for EES vs. PES in 
small vessels. 
Reference vessel diameter < 2.5 mm Reference vessel diameter ≥ 2.5 mm
EES PES RR [95%CI]* EES PES RR [95%CI]* P Interaction
Patient number 681 338 1730 856
TLF¥ 4.4% 7.9% 0.55 [0.33, 0.92] 4.1% 5.5% 0.73 [0.51, 1.06] 0.36
MACE# 4.5% 7.9% 0.57 [0.34, 0.94] 4.2% 5.8% 0.73 [0.51, 1.05] 0.41
Cardiac death or MI§ 2.9% 3.0% 0.94 [0.44, 1.99] 2.2% 2.8% 0.81 [0.49, 1.35] 0.76
MI§ 2.1% 2.7% 0.77 [0.34, 1.75] 1.9% 2.5% 0.77 [0.45, 1.32] 0.99
TLR£ 2.4% 5.5% 0.44 [0.23, 0.85] 2.4% 3.5% 0.69 [0.43, 1.11] 0.27
¥ Target lesion failure = cardiac death, target vessel MI or ischemia-driven TLR
# Major adverse cardiac events = cardiac death, MI or ischemia-driven TLR
§ Myocardial infarction
£ Target lesion revascularization
* RR [95%CI] = relative risk [95% confidence interval]
